{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:56:47Z","timestamp":1791205007352,"version":"4.1.0"},"reference-count":18,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Homologous recombination deficiency (HRD) is a critical indicator of genomic instability; however, the composite HRD score may not reflect the distribution of distinct genomic scar components underlying this phenotype. In this exploratory study, we compared the absolute and relative contributions of loss of heterozygosity (LOH), large-scale state transitions (LST), and telomeric allelic imbalance (TAI) among solid tumors harboring pathogenic or likely pathogenic (P\/LP) variants in BRCA1 or BRCA2. This retrospective study included 76 patients with solid tumors who underwent HRD testing between January 2023 and January 2026. P\/LP variants in homologous recombination repair (HRR) genes, alongside LOH, LST, and TAI scores, were evaluated. The composite HRD score was calculated as LOH + LST + TAI, with values \u2265 56 defined as HRD-positive. Additionally, the relative contribution of each scar component to the total HRD score was determined. Given the small sizes of the BRCA1-only and BRCA2-only subgroups and the heterogeneity of the overall cohort, all gene-group comparisons were considered exploratory and hypothesis-generating. Overall, 21.1% of the cohort was HRD-positive. Patients harboring BRCA1\/2 P\/LP variants displayed a significantly higher median HRD score compared to non-carriers (47.0 vs. 30.0; p = 0.016). When comparing patients with tumors harboring BRCA1-only (n = 9) and BRCA2-only (n = 10) P\/LP variants, LOH was higher in the BRCA2 group (19.0 vs. 5.0; p = 0.036); however, this difference did not retain statistical significance following false discovery rate (FDR) adjustment (q = 0.108). In an exploratory sensitivity analysis restricted to breast and ovarian tumors (BRCA1-only, n = 5; BRCA2-only, n = 9), the LOH\/HRD ratio was higher in the BRCA2 group (0.301 vs. 0.000; p = 0.026; q = 0.039), whereas the LST\/HRD ratio was higher in the BRCA1 group (0.488 vs. 0.310; p = 0.019; q = 0.039). These estimates were based on very small subgroups and should therefore be interpreted cautiously. This exploratory analysis identified differences in the relative distributions of LOH and LST between tumors harboring BRCA1-only and BRCA2-only P\/LP variants, particularly in the breast\/ovarian subset. However, the small and heterogeneous subgroups, together with the absence of systematic assessment of biallelic BRCA1\/2 inactivation, preclude gene-specific or mechanistic conclusions. These observations should be regarded as hypothesis-generating and require validation in larger, tumor-specific, independent cohorts.<\/jats:p>","DOI":"10.3390\/ijms27198851","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:31:31Z","timestamp":1791203491000},"page":"8851","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LOH, LST, and TAI Profiles in Solid Tumors Harboring Pathogenic or Likely Pathogenic BRCA1\/2 Variants: An Exploratory Study"],"prefix":"10.3390","volume":"27","author":[{"given":"Suleyman","family":"Erdogdu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Aydin City Hospital, Efeler, Aydin 09020, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1031-6853","authenticated-orcid":false,"given":"Busra","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, School of Medicine, Aydin Adnan Menderes University, Efeler, Aydin 09010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1651-1940","authenticated-orcid":false,"given":"Seda","family":"Orenay-Boyacioglu","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, School of Medicine, Aydin Adnan Menderes University, Efeler, Aydin 09010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-3020","authenticated-orcid":false,"given":"Olcay","family":"Boyacioglu","sequence":"additional","affiliation":[{"name":"Faculty of Engineering, Aydin Adnan Menderes University, Efeler, Aydin 09010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5445-2649","authenticated-orcid":false,"given":"Ibrahim Halil","family":"Erdogdu","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, School of Medicine, Aydin Adnan Menderes University, Efeler, Aydin 09010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Ibrahim","family":"Meteoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, School of Medicine, Aydin Adnan Menderes University, Efeler, Aydin 09010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pacheco-Barcia, V., Mu\u00f1oz, A., Castro, E., Ballesteros, A.I., Marquina, G., Gonz\u00e1lez-D\u00edaz, I., and Romero-Laorden, N. (2022). The homologous recombination deficiency scar in advanced cancer: Agnostic targeting of damaged DNA repair. Cancers, 14.","DOI":"10.3390\/cancers14122950"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: Concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1526","DOI":"10.1002\/onco.13829","article-title":"Homologous recombination deficiency: Cancer predispositions and treatment implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15330338261469099","DOI":"10.1177\/15330338261469099","article-title":"HRD Score: A promising biomarker for genomic instability evaluation for targeted treatments among pancreatic cancer patients","volume":"25","author":"Wang","year":"2026","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhu, S., Zhao, J., Nie, L., Yin, W., Zhang, Y., Zhao, F., and Zeng, H. (2022). Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P). BMC Med., 20.","DOI":"10.1186\/s12916-022-02430-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","article-title":"Homologous recombination deficiency (HRD) testing landscape: Clinical applications and technical validation for routine diagnostics","volume":"13","author":"Witz","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nogueira Rodrigues, A., Souto, A.K.D.B.A., de Andrade, D.A.P., Gomes, L.M., Koide, S.S., e Silva, R.D.G., and Koyama, F.C. (2025). Homologous recombination deficiency test validation in patients with high-grade advanced ovarian cancer. Front. Mol. Biosci., 12.","DOI":"10.3389\/fmolb.2025.1524594"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Guffanti, F., Mengoli, I., and Damia, G. (2024). Current HRD assays in ovarian cancer: Differences, pitfalls, limitations, and novel approaches. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1405361"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-024-10238-y","article-title":"Homologous recombination deficiency (HRD) diagnostics: Underlying mechanisms and new perspectives","volume":"44","author":"Kechin","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ali, U., Vungarala, S., and Tiriveedhi, V. (2024). Genomic features of homologous recombination deficiency in breast cancer: Impact on testing and immunotherapy. Genes, 15.","DOI":"10.3390\/genes15020162"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ren, L., Yao, R., Hou, T., Liu, C., Zhao, F., Chen, X., and Huang, Y. (2025). Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair\u2013associated gene alterations in solid tumors from a large Asian cohort. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14267-w"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1158\/2767-9764.CRC-24-0316","article-title":"Pan-cancer analysis of homologous recombination deficiency in cell lines","volume":"4","author":"Dodson","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41698-022-00276-6","article-title":"Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)","volume":"6","author":"Rempel","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mark, L.R., Terp, S.K., Krarup, H.B., Thomassen, M., Pedersen, I.S., and B\u00f8gsted, M. (2023). Homologous recombination deficiency detection algorithms: A systematic review. Cancers, 15.","DOI":"10.3390\/cancers15235633"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s43856-025-01308-5","article-title":"Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort","volume":"6","author":"Hadi","year":"2026","journal-title":"Commun. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41698-025-00999-2","article-title":"Homologous recombination deficiency among patients with germline or somatic non-BRCA1\/2 homologous recombination repair gene variations","volume":"9","author":"Li","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cokpinar, S., Erdogdu, I.H., Orenay-Boyacioglu, S., Boyacioglu, O., Kahraman-Cetin, N., and Meteoglu, I. (2024). PIK3CA mutations and co-mutations in operated non-small cell lung carcinoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237472"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8851\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:34:32Z","timestamp":1791203672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":18,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198851"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198851","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]}}}